Adam Feuerstein

Before joining TheStreet in March 2001, Feuerstein covered business software for Upside.com. Prior to that he covered a variety of business beats, including technology and commercial real estate, at the San Francisco Business Times.

 


Feuerstein graduated from Emory University with a bachelor's degree in political science.

 


Recent Articles By The Author

5 Reasons Celgene Should Buy Biogen

5 Reasons Celgene Should Buy Biogen

At a time when healthcare investors seem especially primed for big, transformative biotech M&A, a deal in which Celgene acquires Biogen would be smart, profitable, opportunistic and certainly attention grabbing.

5 Reasons Celgene Should Buy Biogen

5 Reasons Celgene Should Buy Biogen

A merger would be smart, profitable ... and attention-grabbing.

Biotech School: When Cellceutix CEO Rants About 'Criminal' Short, Smart Investors See Red Flags

Biotech School: When Cellceutix CEO Rants About 'Criminal' Short, Smart Investors See Red Flags

CEOs of troubled companies tend to launch public tirades against the 'evil' shorts. The rants are often a smokescreen meant to divert investors' attention from problems.

Bristol-Myers Squibb, Where Art Thou? Not in First-Line Lung Cancer Immunotherapy, Sadly

Bristol-Myers Squibb, Where Art Thou? Not in First-Line Lung Cancer Immunotherapy, Sadly

Bristol-Myers suffered another setback when the pharma giant said it would not seek accelerated approval for a combination of two immunotherapy drugs as a treatment for newly diagnosed lung cancer.

Eli Lilly Acquires CoLucid Pharma, Adds Migraine Drug to Pipeline

Eli Lilly Acquires CoLucid Pharma, Adds Migraine Drug to Pipeline

CoLucid will be acquired for $46.50 per share, a 33% premium to the stock's closing price Tuesday.